Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Thomas Weimer"'
Autor:
Jennifer Krupka, Frauke May, Thomas Weimer, Ingo Pragst, Christoph Kleinschnitz, Guido Stoll, Con Panousis, Gerhard Dickneite, Marc W Nolte
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146783 (2016)
BACKGROUND AND PURPOSE:Ischemic stroke provokes severe brain damage and remains a predominant disease in industrialized countries. The coagulation factor XII (FXII)-driven contact activation system plays a central, but not yet fully defined pathogeni
Externí odkaz:
https://doaj.org/article/9836f5b3bbb9458a890a7684b9626651
Autor:
Anton Zalewski, Arna Andrews, Isabelle Glauser, Marcel Mischnik, Matthew P. Hardy, Anne M Verhagen, Kerstin Emmrich, Sabine Pestel, Con Panousis, Philipp Claar, Victor Turnbull, Chao-Guang Chen, Michael J. Wilson, Gregory T. Bass, Elmar Raquet, Steve K. Dower, Jenny Chia, Thomas Weimer, Vesna Tomasetig
Publikováno v:
Journal of Thrombosis and Haemostasis. 19:2710-2725
BACKGROUND We have recently reported on a recombinant von Willebrand factor (VWF) D'D3 albumin fusion protein (rD'D3-FP) developed to extend the half-life of coagulation factor VIII (FVIII) for the treatment of hemophilia A. Based on predictive model
Publikováno v:
Blood cells, moleculesdiseases. 89
Hemophilia A and hemophilia B are X-linked inherited bleeding disorders caused by a deficiency of coagulation factor VIII and IX, respectively. Standard of care is prophylactic factor replacement therapy; however, the development of neutralizing anti
Autor:
Jason Simmonds, Anna Tjärnlund-Wolf, Holger Lind, Arna Andrews, Philipp Claar, Stefan Schulte, Sabine Pestel, Steven K. Dower, Peter Schmidt, Marcel Mischnik, Thomas Weimer, Vesna Tomasetig, Elmar Raquet, Hans-Wilhelm Beltz
Publikováno v:
Blood Adv
A novel mechanism for extending the circulatory half-life of coagulation factor VIII (FVIII) has been established and evaluated preclinically. The FVIII binding domain of von Willebrand factor (D′D3) fused to human albumin (rD′D3-FP) dose depende
Autor:
Eva Herzog, Michael J. Wilson, Elmar Raquet, Marcel Mischnik, Arna Andrews, Sabine Pestel, Steve K. Dower, Philipp Claar, Thomas Weimer
Publikováno v:
Science meets clinical practice.
Autor:
Hans Will, Gerhild Wildner, Doris Fernholz, Rolf Sprengel, Thomas Weimer, Florian Schödel, Ralf Schneider
Publikováno v:
Molecular Biology of the Hepatitis B Virus ISBN: 9781351074759
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae821d14c4d111666aaf2a4389f7edd0
https://doi.org/10.1201/9781351074759-3
https://doi.org/10.1201/9781351074759-3
Autor:
Thomas Weimer, Hanna Mergner
Publikováno v:
Energy. 88:93-100
Cost efficient power generation from low temperature heat sources requires an optimal usage of the available heat. In addition to the ORC (Organic Rankine Cycles), cycles with ammonia and water as working fluid show promising results regarding effici
Autor:
Jochen Mueller-Cohrs, Sabine Zollner, Stefan Schulte, Gerhard Dickneite, Ingo Pragst, Elmar Raquet, Daniel Schuermann, Thomas Weimer
Publikováno v:
Journal of Thrombosis and Haemostasis
Summary Background Recombinant factor VIIa (rFVIIa) is approved for use in controlling bleeding episodes in people with hemophilia who have developed inhibitors to replacement therapy. Due to its short half-life (t½), frequent injections are require
Publikováno v:
Thrombosis and Haemostasis. 110:931-939
SummaryThe prophylactic treatment of haemophilia B and the management of haemophilia A or B with inhibitors demand frequent administrations of coagulation factors due to the suboptimal half-lives of the products commercially available and currently i
Autor:
Thomas Weimer, Con Panousis, Ingo Pragst, Jennifer Krupka, Christoph Kleinschnitz, Frauke May, Gerhard Dickneite, Guido Stoll, Marc W. Nolte
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 1, p e0146783 (2016)
PLoS ONE, Vol 11, Iss 1, p e0146783 (2016)
Background and purpose Ischemic stroke provokes severe brain damage and remains a predominant disease in industrialized countries. The coagulation factor XII (FXII)-driven contact activation system plays a central, but not yet fully defined pathogeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26808de7f79f783ca2e56a75af022736
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-167370
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-167370